Increasing levels of the MYT1L gene to help treat neurodevelopmental disorders
Antisense oligonucleotide-based upregulation of neurodevelopmental disorder gene MYT1L
This study is looking for ways to boost a gene called MYT1L, which is important for healthy brain development, to help people with MYT1L syndrome and related conditions like autism and ADHD, by using a special technique that can increase the gene's activity.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11067502 on NIH RePORTER |
What this research studies
This research focuses on finding ways to increase the levels of the MYT1L gene, which is important for normal brain development and function. The study aims to use a technique called antisense oligonucleotides (ASOs) to block elements that reduce the stability of MYT1L's mRNA, thereby enhancing its protein production. By understanding how MYT1L levels are regulated, the researchers hope to develop effective therapies for conditions like MYT1L syndrome, which is associated with developmental delays and disorders such as autism and ADHD. Patients may benefit from this research if it leads to new treatment options that improve their developmental outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with MYT1L syndrome or those exhibiting symptoms related to autism spectrum disorder or attention-deficit/hyperactivity disorder.
Not a fit: Patients without genetic mutations affecting the MYT1L gene or those not diagnosed with related neurodevelopmental disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic strategies for patients with MYT1L syndrome and related neurodevelopmental disorders.
How similar studies have performed: While the use of antisense oligonucleotides is a promising approach, this specific application for MYT1L syndrome is novel and has not been extensively tested in prior research.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Gachechiladze, Mariam Alexandra — Washington University
- Study coordinator: Gachechiladze, Mariam Alexandra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.